Management of Ductal Carcinoma In Situ

DCIS Basics - Defining the Dots

• Ductal Carcinoma In Situ (DCIS): A non-invasive breast cancer where malignant epithelial cells are confined to the ductal system, not breaching the basement membrane.
• Precursor lesion: Can progress to invasive ductal carcinoma (IDC) if untreated; considered Stage 0 cancer.
• Clinical presentation: Usually asymptomatic.
  • Most common detection: Suspicious microcalcifications on screening mammography (e.g., pleomorphic, linear, branching).

⭐ The majority of DCIS cases (around 80%) are identified on screening mammography as suspicious calcifications, often before any palpable lump forms.

Diagnosis & Workup - Spotting the Suspects

• Mammography: Primary tool.
  • Classic sign: Microcalcifications (pleomorphic, linear, branching).
  • Less common: Mass, architectural distortion.
• Ultrasound (USG):
  • Adjunct to mammography; guides biopsy for visible lesions.
  • May show intraductal material or be normal.
• MRI:
  • Not routine for diagnosis.
  • Role: Assess extent in dense breasts, high-risk screening.
• Biopsy (Gold Standard):
  • Core Needle Biopsy (CNB): Stereotactic (for calcs) or USG-guided.
  • Specimen radiography confirms calcification retrieval.

⭐ Most DCIS is detected as asymptomatic, screen-detected microcalcifications on mammography.

Risk & Prognosis - Sizing Up the Situation

• Recurrence (post-lumpectomy):
  • Lumpectomy alone: ~25-30% at 10 yrs.
  • Lumpectomy + RT: ↓ to ~15%.
  • ~50% of recurrences are invasive.

⭐ The most significant predictor of local recurrence after breast-conserving surgery for DCIS is achieving negative surgical margins (ideally ≥ 2 mm).

Treatment Pillars - The Action Plan

• Goal: Eradicate DCIS, prevent invasive cancer, minimize recurrence.
• Surgical Options:
  • Breast Conserving Surgery (BCS) / Lumpectomy: Standard. Aim for negative margins (≥ 2mm).
  • Mastectomy: For extensive/multicentric DCIS, contraindications to BCS/RT, or patient choice.
• Sentinel Lymph Node Biopsy (SLNB):
  • Not routine with BCS for pure DCIS.
  • Consider if: mastectomy, high risk of occult invasion (large, high grade, palpable).
• Adjuvant Therapies:
  • Radiotherapy (RT): Standard post-BCS. ↓ local recurrence by ~50%. Omission in select low-risk cases.
  • Endocrine Therapy (ET): For ER+ DCIS (e.g., Tamoxifen). ↓ risk of future breast events.

⭐ For ER+ DCIS, Tamoxifen for 5 years reduces risk of ipsilateral recurrence and contralateral new breast cancer.

Follow‑Up & Future - Staying Vigilant

• Annual mammography indefinitely.
• Clinical Breast Exam (CBE): Every 6-12 months for 5 years, then annually.
• Ipsilateral recurrence risk (DCIS or invasive): ~1-2% per year.
• Contralateral breast cancer risk: ~0.5-1% per year.
• Consider chemoprevention (e.g., Tamoxifen, Aromatase Inhibitors) for ER+ DCIS, especially post-Breast Conserving Therapy (BCT).

⭐ Overall prognosis for DCIS is excellent, with disease-specific survival rates exceeding 98% at 10 years post-diagnosis and treatment.

High‑Yield Points - ⚡ Biggest Takeaways

• DCIS is a non-invasive breast malignancy confined to ducts, precursor to invasive cancer.
• Mammography (microcalcifications) is the primary diagnostic tool for DCIS.
• Breast Conserving Surgery (BCS) followed by Radiotherapy (RT) is standard for most DCIS.
• Mastectomy is indicated for extensive disease, multicentricity, or contraindications to RT.
• Sentinel Lymph Node Biopsy (SLNB) considered with mastectomy or if invasive cancer suspected.
• Endocrine therapy (e.g., Tamoxifen) for ER-positive DCIS reduces recurrence risk.
• Goal: Prevent progression to Invasive Ductal Carcinoma (IDC); excellent prognosis with treatment.